The role of one of the polymorphisms, the GPIIIa PL A1/A2 polymorphism (a Leu [PL A1 ] to Pro [PL A2 ] substitution at position 33 of the GPIIIa β 3 subunit), in the pathogenesis of thromboembolism was studied for several years. Although its relation to thrombotic events remains controversial and no correlation between venous thrombosis and the GPIIIa PL A1/A2 polymorphism was found, several studies report that the presence of the PL A2 allele is associated with the increased risk for arterial thrombosis, particularly for myocardial infarction and restenosis after a revascularization procedure (8) (9) (10) (11) . Furthermore, Feng and associates (12) found that the platelet aggregation can be induced with lower concentrations of ADP and epinephrine in PL A2 carriers in comparison with PL A1 carriers. Similar observations were made by Michelson and associates (7) , who found increased reactivity (measured as increased granule release, GPIIb/IIIa activation, and fibrinogen binding) to low-dose ADP in PL A2 positive platelets.
In the population of Northern European ancestry the prevalence of the PL A2 allele is approximately 25% and the frequency of the PL A2/A2 homozygotes is about 2% (7) . Feng and associates (12) analyzed 1422 patients from the Framingham Offspring Study and established the prevalence of the PL A1/A1 homozygotes, PL A1/A2 heterozygotes, and PL A2/A2 homozygotes to 71.5%, 26.1%, and 2.5%, respectively.
The above reported findings-the association of the PL A2 allele with arterial thrombosis and increased platelet aggregation, its rather high prevalence-suggested the question of whether the GPIIIa PL A1/A2 polymorphism can not be one of the suggested glycoprotein defects involved in the pathogenesis of SPS, particularly in the formation of arterial thrombus in this syndrome. In our study we tried to verify the above presented hypothesis and evaluate the presence of the PL A2 allele in patients with SPS.
We investigated 64 patients (23 men/41 women) age 8 to 69 years (8 to 69 years/8 to 67 years) with a mean age of 41.5 years (42.4 years/41.0 years) who had a positive history of arterial or venous thromboembolic events and in whom the thrombophilic screening did not explain the cause of thromboembolism.
Platelet hyperaggregability was examined by the method of Mammen (6) . Patients treated with drugs blocking the cyclooxygenase were tested after a 14-day period without the medication. The aggregometer PACKS-4 (HELENA Laboratories) was used and every sample was tested with three concentrations of ADP (2.34 µM, 1.17 µM, and 0.58 µM) and epinephrine (11.00 µM, 1.10 µM, and 0.55 µM). The criteria suggested by Mammen and Bick were used to confirm the diagnosis of SPS (1, 3) . Patients with SPS were tested for GPIIIa PL A1/A2 polymorphism. The polymerase chain reaction (PCR) based restriction fragment length polymorphism analysis previously described by Newman et al (13) was used for the detection of the PL A1 and PL A2 alleles.
Of 64 patients enrolled in the study, 9 (14.06%)-4 men and 5 women-were found to have SPS (Table 1) . Two patients had SPS type I, 6 had SPS type II, and 1 had SPS type III. Two patients suffered from venous thrombosis (both from deep venous thrombosis), 4 from arterial thrombosis (1 had stroke, 2 had myocardial infarction, 1 had periferal arterial thrombosis), and 3 had symptoms of both arterial and venous thrombosis. The GPIIIa PL A1/A2 polymorphism was tested in those patients who were diagnosed with SPS. We found PL A2 carriers among the patients with SPS, but not all were positively tested for the PL A2 allele. Four patients were found to be PL A1/A1 homozygotes (2 had arterial, 1 had venous, and 1 had both types of thrombosis), 5 patients were PL A1/A2 heterozygotes (2 with arterial, 1 with venous, and 2 with both types of thrombosis). None of the tested patients was PL A2/A2 homozygote (Table 1) .
Although the relation of the GPIIIa PLA polymorphism to venous thromboembolism is not well defined and most studies failed to establish the PL A2 allele as a risk factor for venous thrombosis (14, 15) , the PL A2 carriers in our study suffered from both arterial and venous thrombotic events. Three of 5 PL A2 carriers suffered from deep venous thrombosis. Furthermore, 3 patients with myocardial infarction were PL A1 homozygotes, although the relation between the PL A2 allele and coronary thrombosis has been described (11) .
Of course, due to the limited number of patients investigated in the study, the above-presented results should be interpreted carefully. The patient group must be extended in order to give a more reliable answer to the proposed hypothesis. However, even these partial results suggest that the GPIIIa PL A1/A2 polymorphism cannot fully explain the pathogenesis of SPS. It seems obvious that other glycoprotein defects or pathophysiological mechanisms also must be considered to explain platelet hyperaggregability in SPS. 
